Federated Hermes, Inc. Global Blood Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$52.76 - $74.49 $72,597 - $102,498	-1,376 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$48.73 - $81.82 $10.3 Million - $17.3 Million	-211,372 Reduced 99.35%	1,376 $87,000
Q1 2020 May 13, 2020	BUY	$41.72 - $87.2 $2.74 Million - $5.73 Million	65,752 Added 44.73%	212,748 $10.9 Million
Q4 2019 Feb 14, 2020	BUY	$45.7 - $81.86 $6.02 Million - $10.8 Million	131,631 Added 856.69%	146,996 $11.7 Million
Q3 2019 Nov 14, 2019	SELL	$45.35 - $57.91 $2.56 Million - $3.28 Million	-56,558 Reduced 78.64%	15,365 $746,000
Q2 2019 Aug 14, 2019	BUY	$52.6 - $63.29 $3.28 Million - $3.95 Million	62,343 Added 650.76%	71,923 $3.78 Million
Q1 2019 May 10, 2019	BUY	$39.99 - $53.48 $383,104 - $512,338	9,580 New	9,580 $507,000
Q3 2018 Nov 13, 2018	SELL	$38.0 - $51.1 $190,000 - $255,500	-5,000 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$38.7 - $50.15 $193,500 - $250,750	5,000 New	5,000 $226,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.